Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis

National Institutes of Health (NIH)

Status and phase: Completed; Phase 1

Conditions: Liver Cirrhosis, Biliary; Cholangitis, Sclerosing

Treatments: Drug: budesonide

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00004842

199/13922

MAYOC-41296 (Other Identifier)

R03DK052344 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

OBJECTIVES: I. Assess the safety and effectiveness of budesonide in patients with primary sclerosing cholangitis or primary biliary cirrhosis experiencing a suboptimal response to ursodeoxycholic acid.

II. Estimate the efficacy of this therapy in these patient groups as a means of evaluating the feasibility of a long-term randomized trial.

Full description

PROTOCOL OUTLINE:

Patients receive budesonide by mouth 3 times daily for a minimum of 6 months. If liver biochemistries become normal, dosage is reduced to once daily. Treatment discontinues after 1 year.

Enrollment: 22 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Pathologically confirmed primary sclerosing cholangitis (PSC) meeting the following criteria:

• Chronic cholestatic disease for at least 6 months
• Liver biopsy within the past 6 months compatible with the diagnosis of PSC Intra and/or extrahepatic biliary duct obstruction, beading, or narrowing

OR

Pathologically confirmed primary biliary cirrhosis (PBC) that is experiencing suboptimal response to ursodeoxycholic acid and meeting the following criteria:

• Chronic cholestatic liver disease for at least 6 months
• Positive antimitochondrial antibody
• No biliary obstruction by ultrasound, CT, or cholangiography
• Prior liver biopsy compatible with diagnosis of PBC
• Received ursodeoxycholic acid for at least 6 months

--Prior/Concurrent Therapy--

Biologic therapy:

• At least 3 months since prior D-penicillamine
• No planned transplantation for at least 1 year

Chemotherapy:

• At least 3 months (6 months for PBC) since prior cyclosporin, colchicine, azathioprine, or methotrexate
• At least 6 months since prior chlorambucil (PBC only)

Endocrine therapy: At least 3 months (6 months for PBC) since prior corticosteroids

Surgery: No prior intraductal stones or operations on the biliary tree except cholecystectomy (PSC only)

Other:

• At least 3 months since prior pentoxifylline, ursodeoxycholic acid, or nicotine (PSC only)
• At least 6 months since prior chenodeoxycholic acid (PBC only)

--Patient Characteristics--

Life expectancy: At least 3 years

Hematopoietic: Not specified

Hepatic:

• Alkaline phosphatase at least 2 times upper limits of normal
• No chronic hepatitis B infection
• No hepatitis C infection
• No autoimmune hepatitis
• Bilirubin no greater than 4 mg/dL (PBC only)

Cardiovascular: No severe cardiopulmonary disease

Other:

• No concurrent advanced malignancy
• At least 3 months since prior inflammatory bowel disease requiring specific treatment except maintenance therapy (PSC only)
• No anticipated need for transplantation within 1 year
• Not pregnant
• No liver disease of other etiology such as:

Chronic alcoholic liver disease

Hemochromatosis

Wilson's disease

Congenital biliary disease

Cholangiocarcinoma

No recurrent ascending cholangitis requiring hospitalization more than 2 times per year (PSC only)

At least 1 year since prior active peptic ulcer

No recurrent variceal bleeds

No spontaneous encephalopathy

No diuretic-resistant ascites

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

22 participants in 1 patient group

Budesonide

Experimental group

Description:

Oral budesonide

Treatment:

Drug: budesonide